Fr-PPIChem: An Academic Compound Library Dedicated to Protein-Protein Interactions.
Bosc N, Muller C, Hoffer L, Lagorce D, Bourg S, Derviaux C, Gourdel ME, Rain JC, Miller TW, Villoutreix BO, Miteva MA, Bonnet P, Morelli X, Sperandio O, Roche P
Publications
In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.
Ariey-Bonnet J, Carrasco K, Le Grand M, Hoffer L, Betzi S, Feracci M, Tsvetkov P, Devred F, Collette Y, Morelli X, Ballester P, Pasquier E
CovaDOTS: In Silico Chemistry-Driven Tool to Design Covalent Inhibitors Using a Linking Strategy.
Hoffer L, Saez-Ayala M, Horvath D, Varnek A, Morelli X, Roche P
From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia.
Saez-Ayala M, Hoffer L, Abel S, Ben Yaala K, Sicard B, Andrieu GP, Latiri M, Davison EK, Ciufolini MA, Brémond P, Rebuffet E, Roche P, Derviaux C, Voisset E, Montersino C, Castellano R, Collette Y, Asnafi V, Betzi S, Dubreuil P, Combes S, Morelli X
Discovery of a PDZ Domain Inhibitor Targeting the Syndecan/Syntenin Protein-Protein Interaction: A Semi-Automated « Hit Identification-to-Optimization » Approach.
Hoffer L, Garcia M, Leblanc R, Feracci M, Betzi S, Ben Yaala K, Daulat AM, Zimmermann P, Roche P, Barral K, Morelli X
Discovery of Small-Molecule Inhibitors of the PTK7/β-Catenin Interaction Targeting the Wnt Signaling Pathway in Colorectal Cancer.
Ganier L, Betzi S, Derviaux C, Roche P, Dessaux C, Muller C, Hoffer L, Morelli X, Borg JP
CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.
Carrasco K, Montersino C, Derviaux C, Saez-Ayala M, Hoffer L, Restouin A, Castellano R, Casassa J, Roche P, Pasquier E, Combes S, Morelli X, Collette Y, Betzi S
Inhibiting Type VI Secretion System Activity with a Biomimetic Peptide Designed To Target the Baseplate Wedge Complex.
Cherrak Y, Filella-Merce I, Schmidt V, Byrne D, Sgoluppi V, Chaiaheloudjou R, Betzi S, Morelli X, Nilges M, Pellarin R, Durand E
Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread.
Garcia M, Hoffer L, Leblanc R, Benmansour F, Feracci M, Derviaux C, Egea-Jimenez AL, Roche P, Zimmermann P, Morelli X, Barral K
The NANOTUMOR consortium – Towards the Tumor Cell Atlas.
Colin F, Schauer K, Hamiche A, Martineau P, Borg JP, Bednar J, Bertolin G, Camoin L, Collette Y, Dimitrov S, Fournier I, Hyenne V, Mendoza-Parra MA, Morelli X, Rondé P, Sumara I, Tramier M, Schultz P, Goetz JG
Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loading with syndecan and EpCAM cargo.
Leblanc R, Kashyap R, Barral K, Egea-Jimenez AL, Kovalskyy D, Feracci M, Garcia M, Derviaux C, Betzi S, Ghossoub R, Platonov M, Roche P, Morelli X, Hoffer L, Zimmermann P
Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors.
Hernandez J, Hoffer L, Coutard B, Querat G, Roche P, Morelli X, Decroly E, Barral K
Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches.
Hoffer L, Muller C, Roche P, Morelli X